Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04732728 · ClinicalTrials.gov registry record
LUX-Dx Insertable Cardiac Monitor Remote Programming and Performance Study
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 727
- Enrollment target
NCT04732728: Completed study, sponsored by Boston Scientific Corporation.
NCT04732728 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 727 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04732728 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 727 participants
- Enrollment target
Study Summary
The LUX-Dx PERFORM Study had two primary objects which were (1) to characterize, in a general patient population, the utilization of the remote programming feature of the Boston Scientific (BSC) Insertable Cardiac Monitor (ICM) device and (2) to collect data to characterize the performance of arrhythmia detection algorithms. Data was also collected to characterize the ICM system related safety events.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 727 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2023-05-18 |
What the finished NCT04732728 record still lists
NCT04732728 is an observational study that tracks outcomes without assigning an intervention. The registered 727 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04732728 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04732728 about?
NCT04732728 is a clinical study titled "LUX-Dx Insertable Cardiac Monitor Remote Programming and Performance Study". The LUX-Dx PERFORM Study had two primary objects which were (1) to characterize, in a general patient population, the utilization of the remote programming feature of the Boston Scientific (BSC) Insertable Cardiac Monitor (ICM) device and (2) to collect data to characterize the performance of arrhyt...
What is the current status of trial NCT04732728?
This trial is currently completed. The enrollment target is 727 participants. The study started on 2021-03-05. Estimated completion is 2023-05-18.
Who is sponsoring clinical trial NCT04732728?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- NCT06433765 · 728 participants
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- NCT06660342 · 728 participants
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI